O
Orion Biotechnology
A clinical stage biotechnology company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases
About Orion Biotechnology
Orion Biotechnology is a pioneering company in the field of drug discovery and development, specializing in G Protein Coupled Receptor (GPCR) targeted therapies. The company focuses on creating treatments for metabolic and immunological diseases through precision engineering of small protein ligands that target GPCRs. Orion's innovative approach is supported by one of the fastest drug discovery platforms in the industry, offering a significant opportunity to develop a new generation of GPCR-targeted medicines. The company's lead compound, OB 002, is a GPCR analog of CCL5, demonstrating best-in-class potency and a proven mechanism of action. This compound has broad applicability across a range of serious diseases, including cancer, infectious diseases, and neuroinflammatory disorders.
Orion Biotechnology serves clients in the biopharmaceutical sector, particularly those focused on oncology, immunology, and other serious diseases. The company operates in the global healthcare market, leveraging its advanced drug discovery platform to develop high-value GPCR-targeted therapies. Orion's business model revolves around the discovery, development, and commercialization of these therapies, generating revenue through partnerships, licensing agreements, and direct sales of its proprietary compounds.
The company is led by a highly experienced team with world-leading expertise in GPCR pharmacology and peptide protein engineering. Orion Biotechnology is committed to advancing a diversified pipeline of potential antagonist and agonist therapies, aiming to unlock the therapeutic potential of previously undruggable GPCRs.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCEquity / VC | Jul 2024 | $743K | $3M | Undisclosed | ↗ |
| SERIES AEquity / VC | Mar 2023 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Orion Biotechnology is 2.2K monthly website visits, up 233.3% over the last three months. Orion Biotechnology's team declined 5.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Orion Biotechnology in the Ottawa ecosystem
The Orion Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
The National Centre for Research and Development
Series A2 investors entered at this stage
Keiretsu Forum
HaloHealth
Other known investors5 additional known investors
University of Geneva
Cantilever Business Partners
EPFL Innovation Park
Globivest- KSKYTO Technology & Life Science
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Orion Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Orion Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









